Login to Your Account


Plug-drug shrug: Wall Street less than sweet on Ocular phase II, III data but analysts glad

By Randy Osborne
Staff Writer

Friday, October 23, 2015

A pair of top-line datasets from what analysts called a successful phase III trial in allergic conjunctivitis and a phase IIb study said to have done its job in glaucoma/ocular hypertension (OH) apparently didn't convince investors in Ocular Therapeutix Inc., who took shares (NASDAQ:OCUL) down 52.3 percent Friday, or $7.88, to close at $7.18.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription